VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Vertex Pharmaceuticals's Gross Profit for the three months ended in Sep. 2024 was $2,379 Mil. Vertex Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $2,772 Mil. Therefore, Vertex Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2024 was 85.84%.
The historical rank and industry rank for Vertex Pharmaceuticals's Gross Margin % or its related term are showing as below:
During the past 13 years, the highest Gross Margin % of Vertex Pharmaceuticals was 89.49%. The lowest was 86.12%. And the median was 87.92%.
Vertex Pharmaceuticals had a gross margin of 85.84% for the quarter that ended in Sep. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vertex Pharmaceuticals was 0.20% per year.
The historical data trend for Vertex Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial | 86.84 | 88.14 | 88.06 | 87.90 | 87.21 |
Vertex Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Margin % | Get a 7-Day Free Trial | 87.17 | 85.38 | 87.27 | 85.94 | 85.84 |
For the Biotechnology subindustry, Vertex Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue.
Vertex Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as
Gross Margin % (A: Dec. 2023 ) | = | Gross Profit (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 8607 | / | 9869.2 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (9869.2 - 1262.2) | / | 9869.2 | |
= | 87.21 % |
Vertex Pharmaceuticals's Gross Margin for the quarter that ended in Sep. 2024 is calculated as
Gross Margin % (Q: Sep. 2024 ) | = | Gross Profit (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | 2379.3 | / | 2771.9 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (2771.9 - 392.6) | / | 2771.9 | |
= | 85.84 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vertex Pharmaceuticals (NAS:VRTX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vertex Pharmaceuticals had a gross margin of 85.84% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
David Altshuler | officer: EVP, Global Research and CSO | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP, BILLERICA MA 01820 |
Reshma Kewalramani | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Jonathan Biller | officer: EVP and Chief Legal Officer | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Jeffrey M Leiden | director | 15 N BEACH ROAD, HOBE SOUND FL 33455 |
Sangeeta N. Bhatia | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Carmen Bozic | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Bruce I Sachs | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Atkinson Edward Morrow Iii | officer: EVP, Chief Technical Ops. Off. | C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
Ourania Tatsis | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Kristen Ambrose | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
Stuart A Arbuckle | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139 |
Amit Sachdev | officer: SVP, Public Policy,Gov Affairs | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Michel Lagarde | director | 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017 |
Terrence C Kearney | director | IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045 |
From GuruFocus
By GuruFocus Research • 08-01-2024
By Business Wire • 06-14-2024
By GuruFocus News • 11-13-2024
By GuruFocus Research • 07-12-2024
By GuruFocus Research • 07-31-2024
By Business Wire • 09-26-2024
By GuruFocus News • 10-03-2024
By GuruFocus Research • 07-24-2024
By Business Wire • 07-01-2024
By Business Wire • 08-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.